Pharmaceuticals
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, met...
2026-11-14 11:48
5069
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
JILIN, China, Nov. 12, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, to...
2026-11-13 05:30
2009
Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) in Chronic Spontaneous Urticaria at ACAAI 2026
* Post hoc analyses of the Phase 3 study of CT-P39 (omalizumab-igec) found that improvements in quality of life, as assessed by the Dermatology Life Quality Index, emerged earlier than disease activity responses, with 41.7% of patients maintaining disease control and quality of life up to 16 we...
2026-11-12 23:00
1697
First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
SYDNEY, Nov. 12, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the United State...
2026-11-12 22:01
1306
Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...
2026-11-12 11:11
561
Accro Bioscience Announces First Patient Enrolled in Phase II/III Clinical Trial of Highly Selective TYK2/JAK1 Inhibitor AC-201 for Non-Segmental Vitiligo
NEW YORK and SUZHOU, China, Nov. 11, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro Bioscience" or "Accro") today announced that its partner's subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharma Industrial Development", a controlled subsidiary...
2026-11-11 18:39
510
IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.-China Clinical Development
First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated directly in the United States SHANGHAI, NANJING, China, and PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a com...
2026-11-11 13:02
860
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
* PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically meaningful improvements in certain clinical outcome assessments, including physical function ...
2026-11-11 12:05
1707
SAMILBIO Moves to Launch 'NpillAI' This Year, Pairing AI Consultation with Pharmacist Review
Platform provides nutrition management information based on health checkup and medication data; kiosk integration development completed SEOUL, South Korea, Nov. 10, 2026 /PRNewswire/ -- SAMILBIO is preparing to launch "NpillAI", a health functional food platform that combines AI chat consultatio...
2026-11-11 09:00
1172
Sino Biological Advances AI-Designed Molecule Validation with 4RISE™
Faster Expression. Deeper Validation. Integrated Support. HOUSTON, Nov. 10, 2026 /PRNewswire/ -- AI can generate protein candidates at an unprecedented speed, but experimental validation remains essential to determine whether they properly express, bind targets, and demonstrate the desired biolo...
2026-11-10 23:21
1969
Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, today anno...
2026-11-10 16:55
3161
PharmaBlock CMC Lifecycle Strategy Forum: Smarter Decisions Across the Drug Development Lifecycle
Lifecycle-based CMC strategies can help biotech companies balance speed, risk and long-term asset value as programs advance globally NANJING, China, Nov. 9, 2026 /PRNewswire/ -- PharmaBlock hosted its CMC Lifecycle Strategy Forum in Nanjing on November 5 and 6, bringing together experienced phar...
2026-11-09 16:29
1910
Timing Affects Speed, Not Total Exposure
CureGene Presents Evategrel China–US PK/PD and Food-Effect Data at AHA 2026 SHANGHAI, Nov. 8, 2026 /PRNewswire/ -- Clopidogrel does not work the same way in every patient. In East Asian populations the gap is wider still: a share of patients get too little platelet inhibition at the standard dose...
2026-11-09 08:51
1542
VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity
SEOUL, South Korea, Nov. 6, 2026 /PRNewswire/ -- Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park ...
2026-11-07 01:00
4598
NORROY BIOSCIENCE Showcased 11 Research Presentations at EANM' 26, Advancing Radiopharmaceutical Innovation and Global Ecosystem Collaboration
WUXI, China, Nov. 5, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, today announced that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at ...
2026-11-05 18:00
2777
Dizal to Present Latest Clinical Data at ASH 2026
* Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. * Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL SHANGH...
2026-11-05 16:16
2416
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Adm...
2026-11-05 12:19
2957
ONE OF THE WORLD'S FIRST PERSONALISED BRAIN STIMULATION STUDIES SHOWS PROMISE FOR SEVERE OCD WITH NUH AND NUS MEDICINE EXTENDING THE APPROACH TO DEPRESSION AND ANXIETY
Building on an established NUH–NUS Medicine collaboration, the work combines clinical expertise and cutting‑edge neuroimaging to improve outcomes for patients who have not responded to standard treatments SINGAPORE, Nov. 4, 2026 /PRNewswire/ -- Mental health treatments such as transcranial magne...
2026-11-05 08:05
2285
Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA PharmaceuticalCo., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A is a no...
2026-11-04 14:30
3448
IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial arrival of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. FUCASO was approved by Singapore's Health Sciences Authorit...
2026-11-04 12:59
3343
Week's Top Stories
Most Reposted
vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
[Picked up by 1183 media titles]
2026-11-13 22:11
Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
[Picked up by 1170 media titles]
2026-11-12 23:00
The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1168 media titles]
2026-11-14 13:23
Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00Most Read
DomoAI Launches InkoAI Agent - One Sentence to Ready-to-Post Video
2026-11-13 13:00
132653
Royal Bank of Canada announces agreement to acquire Yarra Capital Management
2026-11-09 21:00
10284
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
2026-11-09 23:00
9528
Poppi Founders Launch Hydration Brand jetty: NYSE Content Update
2026-11-10 22:17
7991
